Program
Furosemide
Also written as “Furosemide 40 mg”, “SQIN-Furosemide” and “CLS006 (Furosemide) Topical Gel”.
Its studies are mostly in Heart Failure · Warts · Liver Cirrhosis · Pulmonary Arterial Hypertension · Diabetes Mellitus, led by 7 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 70 open or running | phase 1since Sep 3, 2014 | Sep 3, 2014 | none ahead |
| Mannkind | 20 open or running | phase 2since Dec 9, 2014 | Dec 9, 2014 | none ahead |
| Maruho | 20 open or running | phase 3since Nov 21, 2016 | Dec 19, 2014 | none ahead |
| PT Bio Farma | 10 open or running | no phasesince Jul 18, 2021 | Jul 18, 2021 | none ahead |
| Sanofi | 10 open or running | phase 1since Oct 30, 2012 | Oct 30, 2012 | none ahead |
| SQ Innovation | 10 open or running | phase 1since Nov 18, 2025 | Nov 18, 2025 | none ahead |
| Sun Pharmaceutical Industries | 10 open or running | no phasesince Oct 22, 2008 | Oct 22, 2008 | none ahead |
Also a collaborator on its studies: parexel, bdd-pharma-ltd, pt-pharma-metric-labs and cssi-life-sciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 1 study since Oct 22, 2008.
- Oct 30, 2012Sanofi's first study: phase 1 study in Renal InsufficiencyNew to SanofiSanofi · NCT01724788 · 12 enrolled · Canada
- Sep 3, 2014Boehringer Ingelheim's first study: phase 1 study in HealthyNew to Boehringer IngelheimBoehringer Ingelheim · NCT02231931 · 24 enrolled · Germany
- Dec 9, 2014Mannkind's first study: phase 2 study in Heart FailureNew to MannkindMannkind · NCT02350725 · 10 enrolled · Netherlands
- Dec 19, 2014Maruho's first study: phase 2 study in Cutaneous WartsNew to MaruhoMaruho · NCT02333643 · 81 enrolled · Netherlands
- Oct 12, 2015Phase 1 study in HealthyBoehringer Ingelheim · NCT02574845 · 18 enrolled · Germany
- Aug 1, 2016Phase 1 study in HealthyBoehringer Ingelheim · NCT02854527 · 30 enrolled · Germany
- Nov 21, 2016Phase 3 study in Cutaneous Common WartsMaruho · NCT02971891 · 484 enrolled · United States
- Oct 6, 2017Phase 1 study in HealthyBoehringer Ingelheim · NCT03307252 · 45 enrolled · Germany
- Nov 7, 2019Phase 1 study in HealthyMannkind · NCT04161482 · 39 enrolled · United States
- Oct 15, 2020Phase 1 study in HealthyBoehringer Ingelheim · NCT04590937 · 15 enrolled · Germany
- Jul 18, 2021PT Bio Farma's first study: no phase study in Drug UseNew to PT Bio FarmaPT Bio Farma · NCT04982874 · 24 enrolled · Indonesia
- Feb 14, 2023No phase study in Liver CirrhosisBoehringer Ingelheim · NCT05741372 · 28 enrolled · Germany
- Jul 11, 2024Phase 1 study in HealthyBoehringer Ingelheim · NCT06504862 · 32 enrolled · Germany
- Nov 18, 2025SQ Innovation's first study: phase 1 study in HealthyNew to SQ InnovationSQ Innovation · NCT07269496 · 16 enrolled · United Kingdom
TargetBeta
“Sodium-(potassium)-chloride cotransporter 2 inhibitor”ChEMBL 37, by rule
Other programs on SLC12A1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Torsemiderule | sarfez-pharmaceuticals-inc | phase 4 | 13 |
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07269496Healthy · United Kingdom | 1 | Completed | SQ Innovation | Mar 9, 2026 | 16 |
| NCT06504862Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Oct 3, 2024 | 32 |
| NCT05741372Liver Cirrhosis · Germany | – | Completed | Boehringer Ingelheim | Dec 18, 2024 | 28 |
| NCT04982874Drug Use · Indonesia | – | Completed | PT Bio Farma | Jan 17, 2020 | 24 |
| NCT04590937Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Jan 11, 2021 | 15 |
| NCT04161482Healthy · United States | 1 | Completed | Mannkind | Jun 24, 2020 | 39 |
| NCT03307252Healthy · Germany | 1 | Completed | Boehringer Ingelheim | May 2, 2018 | 45 |
| NCT02971891Cutaneous Common Warts · United States | 3 | Completed | Maruho | Apr 16, 2018 | 484 |
| NCT02854527Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Nov 11, 2016 | 30 |
| NCT02574845Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Dec 9, 2015 | 18 |
| NCT02333643Cutaneous Warts · Netherlands | 2 | Completed | Maruho | Aug 2015 | 81 |
| NCT02350725Heart Failure · Netherlands | 2 | Completed | Mannkind | Jun 2015 | 10 |
| NCT02231931Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Jan 1, 2015 | 24 |
| NCT01724788Renal Insufficiency · Canada | 1 | Completed | Sanofi | Jan 2013 | 12 |
| NCT00778180Healthy · United States | – | Completed | Sun Pharmaceutical Industries | Oct 2005 | 44 |
How it is read
Names in the registry
- “Furosemide”, 16 entries
- “Furosemide 40 mg”, 2 entries
- “SQIN-Furosemide”, 1 entry
- “CLS006 (Furosemide) Topical Gel”, 1 entry
- “Lasix®”, 1 entry
Conditions, from the studies’ own filings
- Heart Failure, 4 studies
- Warts, 2 studies
- Liver Cirrhosis, 1 study
- Pulmonary Arterial Hypertension, 1 study
- Diabetes Mellitus, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.